Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma.

MLA

Iyer, Priyanka C., et al. “Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma.” JCO Precision Oncology, vol. 2, Dec. 2018. EBSCOhost, https://doi.org/10.1200/PO.18.00173.

APA

Iyer, P. C., Cote, G. J., Hai, T., Gule-Monroe, M., Bui-Griffith, J., Williams, M. D., Hess, K., Hofmann, M.-C., Dadu, R., Zafereo, M., Busaidy, N. L., Ferrarotto, R., Subbiah, V., Gross, N., Gunn, B. G., Skinner, H. D., Garden, A. S., & Cabanillas, M. E. (2018). Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precision Oncology, 2. https://doi.org/10.1200/PO.18.00173

Chicago

Iyer, Priyanka C, Gilbert J Cote, Tao Hai, Maria Gule-Monroe, Jacquelin Bui-Griffith, Michelle D Williams, Kenneth Hess, et al. 2018. “Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma.” JCO Precision Oncology 2 (December). doi:10.1200/PO.18.00173.